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Summary  Nitazoxanide  is  a broad-spectrum  antiviral  agent  undergoing  clinical
development  for  treatment  of  inﬂuenza  and  other  viral  respiratory  infections.
Nitazoxanide  exhibits  in  vitro  activity  against  Middle  East  respiratory  syndrome
coronavirus  (MERS-CoV)  and  other  coronaviruses,  inhibiting  expression  of  the  viral
N  protein.  Nitazoxanide  also  suppresses  production  of  pro-inﬂammatory  cytokines
in  peripheral  blood  mononuclear  cells  and  suppresses  interleukin  6  production  in
mice.  Having  been  used  extensively  in  clinical  trials  and  in  post-marketing  expe-
rience,  nitazoxanide  is  an  attractive  drug  candidate  for  treatment  of  Middle  East
respiratory  syndrome.  Future  research  should  include  in  vitro  mechanism  studies,
animal  models  of  MERS-CoV  infection,  clinical  trials,  including  dose-ranging  trials,
and  evaluation  of  combination  therapy  with  other  potential  MERS-CoV  antivirals.
©  2016  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Limited.  All  rights  reserved.
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iddle  East  respiratory  syndrome  coronavirus
MERS-CoV)  is  an  emerging  viral  disease  of  global
oncern.  More  than  three  years  after  the  ﬁrst
iscovery of  MERS-CoV  in  2012,  fundamental  ques-
ions related  to  its  epidemiology,  pathogenesis,
mmune responses  and  optimal  treatment  remain
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876-0341/© 2016 King Saud Bin Abdulaziz University for Health Scienanswered.  Nevertheless,  it  is  associated  with  a
igh rate  of  mortality  and  there  is  no  approved
ntiviral treatment.  Host-directed  therapies  and
he repurposing  of  existing  drugs  have  been  pro-
osed as  promising  strategies  for  the  development
f MERS-CoV-speciﬁc  antiviral  therapy  [1].
Nitazoxanide is  a broad-spectrum  antiviral  agent
ndergoing  development  for  the  treatment  of
nﬂuenza  and  other  viral  respiratory  infections.
riginally developed  as  an  antiprotozoal  agent,
mmediate-release  dosage  formulations  of  nitazox-
nide  are  licensed  in  the  United  States  for  the
nces. Published by Elsevier Limited. All rights reserved.
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treatment  of  intestinal  infections  caused  by  Cryp-
tosporidium  parvum  and  throughout  Latin  America,
India, Bangladesh  and  Egypt  as  a  broad-spectrum
antiparasitic  agent.  A  new  extended-release  oral
tablet has  been  developed  to  deliver  the  drug  sys-
temically,  and  nitazoxanide  is  being  repurposed
for use  in  treating  viral  respiratory  infections.  It
is presently  undergoing  Phase  3 clinical  develop-
ment for  treating  acute  uncomplicated  inﬂuenza
[2].
In vitro,  tizoxanide,  the  active  circulating
metabolite  of  nitazoxanide,  inhibits  the  repli-
cation of  a  broad  range  of  inﬂuenza  A  and  B
strains including  inﬂuenza  A  subtypes  H1N1,  H3N2,
H3N2v, H3N8,  H5N9,  H7N1  and  oseltamivir-  and
amantadine-resistant  strains.  The  concentrations
required to  inhibit  viral  replication  by  50%  (IC50s)
are between  0.2  and  1.5  g/ml  in  multiple  human
and canine  cell  lines  using  single-step  virus  growth
with high  multiplicity  of  infection  (5  PFU/cell)  and
multi-step  growth  with  low  multiplicity  of  infec-
tion (0.001  PFU/cell).  These  IC50 concentrations
are easily  achieved  in  humans  following  adminis-
tration of  nitazoxanide  extended-release  tablets,
as peak  and  trough  plasma  concentrations  during
repeated  twice  daily  dosing  have  been  reported
to be  4.6  and  0.8  g/ml,  respectively.  Tizoxanide
acts synergistically  with  oseltamivir  and  zanamivir
in inhibiting  in  vitro  replication  of  inﬂuenza  viruses,
and it  exhibits  a  high  barrier  to  resistance  with  no
decrease  in  sensitivity  to  inﬂuenza  A  viruses  after
passage  for  30  days  in  increasingly  sub-inhibitory
concentrations  of  drug  [2—4].
In addition  to  inﬂuenza  viruses,  tizoxanide
inhibits replication  of  a  broad  range  of  other  RNA
and DNA  viruses  in  cell  culture  assays,  including
respiratory syncytial  virus,  parainﬂuenza,  corona-
virus, rotavirus,  norovirus,  hepatitis  B,  hepatitis
C, dengue,  yellow  fever,  Japanese  encephalitis
virus and  human  immunodeﬁciency  virus  [2]. The
broad-spectrum  antiviral  activity  of  tizoxanide
is attributed  to  interference  with  host-regulated
pathways  involved  in  viral  replication,  rather  than
a virus-targeted  mechanism.  These  pathways  may
include interferon  or  mTORC1  signaling  pathways
[2,5].  In the  case  of  inﬂuenza,  tizoxanide  ultimately
blocks the  maturation  of  viral  hemagglutinin  at  the
post-translational  stage.  It  does  not  affect  the  neu-
raminidase  glycoprotein  (the  target  of  oseltamivir,
zanamivir and  peramivir)  or  the  M2  protein  (the
target  of  amantadine),  and  it  has  no  effect  on
viral infectivity,  adsorption  or  entry  into  target  cells
[3].
Importantly,  nitazoxanide  has  been  studied
extensively in  humans  and  has  undergone  preclin-
ical  and  clinical  testing  required  for  licensure  in  the
n
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nited  States  as  a treatment  of  diarrhea  caused
y Cryptosporidium  parvum  and  Giardia  lamblia.
xposure  in  clinical  trials  has  included  speciﬁc
xperience in  patients  with  inﬂuenza  and  inﬂuenza-
ike illnesses  and  extended  courses  of  treatment  (up
o 48  weeks)  in  patients  with  chronic  hepatitis  C.
orldwide,  it  is  estimated  that  more  than  150  mil-
ion people  have  been  treated  with  nitazoxanide
or the  treatment  of  intestinal  parasitic  infections
2].
n vitro activity against MERS-CoV and
ther coronaviruses
n  vitro  studies  have  shown  that  tizoxanide  inhibits
eplication  of  canine  coronavirus  S-378  grown  in
72 cells  with  an  IC50 of  1  g/ml  [2]. Other  studies
ave shown  that  nitazoxanide  inhibits  murine  coro-
avirus,  mouse  hepatitis  virus  strain  A59  (MHV-A59),
ovine  coronavirus  strain  L9  (BCoV-L9)  and  human
nteric coronavirus  4408  (HECoV-4408)  grown  in
ouse astrocytoma  DBT  and  ﬁbroblast  17Cl-1  cells
ith IC50s  of  approximately  0.3  g/ml.  In  these
tudies, nitazoxanide  inhibited  expression  of  the
iral N  protein  [7].
The  parent  compound,  nitazoxanide,  and  the
etabolite,  tizoxanide,  generally  show  similar
nhibitory activity  against  viruses  in  vitro.  Both
ompounds  have  been  shown  to  inhibit  MERS-
oV cultured  in  LLC-MK2  cells  with  IC50s  of  0.92
nd 0.83  g/ml  for  nitazoxanide  and  tizoxanide,
espectively. Notably,  these  in  vitro  IC50s  are  similar
o those  observed  for  inﬂuenza  and  other  viruses.
ffect on production of
ro-inﬂammatory cytokines, including
nterleukin 6 (IL-6)
n  addition  to  its  antiviral  activity,  nitazox-
nide inhibits  the  production  of  pro-inﬂammatory
ytokines  TNF-,  IL-2,  IL-4,  I-5,  IL-6,  IL-8  and  IL-
0 in  peripheral  blood  mononuclear  cells  (PBMCs)
Romark Laboratories,  personal  communication
6]).  In  vivo,  oral  administration  of  nitazoxanide  in
ice at  a dose  of  100  mg/kg  given  two  hours  before
 1-mL  intraperitoneal  injection  of  4%  thioglycol-
ate (TG)  reduced  plasma  IL-6  levels  six  hours  after
G injection  by  90%  compared  with  vehicle-treated
ice [8]. The  relevance  of  these  data  to  humans
as not  been  studied,  but  these  data  suggest  that
itazoxanide  could  improve  outcomes  in  patients
nfected with  MERS-CoV  by  suppressing  overpro-
uction of  pro-inﬂammatory  cytokines,  including
L-6.
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Hitazoxanide,  a  new  drug  candidate  
uman clinical trials in viral respiratory
nfections
itazoxanide  extended-release  tablets  are  cur-
ently undergoing  clinical  development  for  the
reatment  of  acute  uncomplicated  inﬂuenza.
A phase  2b/3  randomized,  double-blind,  placebo
ontrolled  trial  was  conducted  in  74  outpatient  clin-
cs in  the  United  States  between  December  2010
nd May  2011.  Subjects  who  were  12—65  years  of
ge with  fever  ≥38 ◦C  and  at  least  one  respira-
ory symptom  and  one  constitutional  symptom  of
nﬂuenza  were  enrolled  within  48  h  of  symptom
nset while  ﬂu  was  circulating  in  the  community.
ubjects who  had  been  vaccinated  for  seasonal
nﬂuenza and  those  at  high-risk  for  inﬂuenza-
elated complications  were  excluded.  The  subjects
eceived  either  600  mg  of  nitazoxanide,  300  mg  of
itazoxanide  or  placebo  orally  twice  daily  for  ﬁve
ays and  were  followed  for  28  days.  Each  subject
aintained a  diary  and  graded  each  of  nine  symp-
oms  as  absent,  mild,  moderate  or  severe  twice
aily for  seven  days,  or  longer  if  all  symptoms  had
ot returned  to  absent  or  mild  by  day  7.  The  primary
ndpoint was  the  time  from  the  ﬁrst  dose  until  the
lleviation  of  symptoms  (all  symptoms  mild  or  mod-
rate for  at  least  24  h).  The  primary  analysis  was  by
ntention-to-treat  for  subjects  with  inﬂuenza  infec-
ion conﬁrmed  by  RT-PCR  or  culture  at  baseline  [9].
A total  of  624  subjects  were  enrolled,  257  of
hom had  inﬂuenza  identiﬁed  from  nasopharyn-
eal swabs  collected  at  baseline.  Subjects  who
eceived  nitazoxanide  experienced  shorter  times
o alleviation  of  symptoms  compared  with  sub-
ects who  received  placebo.  The  median  times
rom ﬁrst  dose  to  symptom  alleviation  were  95.5  h
95% CI  84.0—108.0;  p  =  0.0084)  for  subjects  who
eceived  600  mg  of  nitazoxanide  and  109.1  h (95%
I 96.1—129.5;  p  =  0.521)  for  subjects  who  received
00 mg  of  nitazoxanide,  compared  with  116.7  h
95% CI  108.1—122.1)  for  subjects  who  received
lacebo. The  lack  of  statistical  signiﬁcance  in  the
ow dose  group  may  have  been  due  to  a  lack  of
tatistical power.  Adverse  events  were  similar  for
he three  groups,  the  most  common  being  headache
eported by  24  subjects  (11%)  in  the  placebo  group,
2 subjects  (6%)  in  the  low-dose  group  and  17  sub-
ects (8%)  in  the  high-dose  group,  and  diarrhea
eported by  7  subjects  (3%)  in  the  placebo  group,  4
ubjects  (2%)  in  the  low-dose  group  and  17  subjects
8%) in  the  high-dose  group  [9].
Based upon  data  from  the  Phase  2b/3  trial,
itazoxanide extended-release  tablets  (600  mg)
dministered  twice  daily  for  ﬁve  days  are  under-
oing Phase  3  clinical  development  for  treatment
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f  acute  uncomplicated  inﬂuenza.  Nitazoxanide  is
eing studied  as  a  monotherapy  and  in  combination
ith oseltamivir  [3].
ecommendations for future research
xisting  data  that  suggest  a  potential  role  for  nita-
oxanide in  treating  MERS-CoV  include  (i)  in  vitro
ctivity  of  nitazoxanide  against  MERS-CoV  and  other
oronaviruses,  (ii)  inhibition  of  pro-inﬂammatory
ytokines in  PBMCs  and  inhibition  of  IL-6  produc-
ion in  mice,  (iii)  activity  in  reducing  the  duration
f symptoms  of  inﬂuenza  in  humans,  and  (iv)  a
avorable  safety  proﬁle  demonstrated  in  clinical  tri-
ls and  in  widespread  post-marketing  use.  Future
esearch  should  include:
 In vitro  studies  of  the  effect  of  nitazoxanide  on
viral proteins  to  further  elucidate  the  mechanism
of action  against  coronaviruses.
 Animal  models  of  MERS-CoV  infection.
 Clinical  trials  that  evaluate  different  doses  of
nitazoxanide.
 Combination  therapies  of  nitazoxanide  with
other proposed  antivirals  for  MERS-CoV  should  be
studied in  vitro  and  then  potentially  in  clinical
trials.
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